Kiora Pharmaceuticals, Inc. KPRX
Kiora Pharmaceuticals, Inc. (Nasdaq: KPRX) is an ophthalmology drug developer. Its lead program, KIO-301, is in Phase 2 for Retinitis pigmentosa. Its next catalyst on record is KIO-401: Kiora plans to initiate a multinational Phase 3 registration trial of KIO-401 in CRAO in 2027, targeting more than 100 patients. (2027).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: KIO-401 — Kiora plans to initiate a multinational Phase 3 registration trial of KIO-401 in CRAO in 2027, targeting more than 100 patients. (2027). 4 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| KIO-301 (ABACUS-2) | Retinitis pigmentosa | small molecule | Phase 2 |
| KIO-104 (KLARITY) | Posterior non-infectious uveitis / retinal inflammation | small molecule | Phase 2 |
| KIO-101 | Ocular inflammation (paused) | small molecule | Phase 1 |
Recent results and decisions
- Oct 29, 2026positive Senju's Phase 2a study of KIO-401 in CRAO in Japan demonstrated a statistically significant improvement in visual acuity versus a prospective registry (p=0.0398).
KIO-401 demonstrated a statistically significant improvement from baseline in Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity compared with a prospective, observational registry (p=0.0398).
Filing - Oct 29, 2026positive KIO-401 demonstrated a statistically significant improvement in visual acuity from baseline compared with a prospective registry (p=0.0398) in a Phase 2a CRAO study in Japan conducted by Senju.
KIO-401 demonstrated a statistically significant improvement from baseline in Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity compared with a prospective, observational registry (p=0.0398).
Filing - Oct 29, 2026positive KIO-401 demonstrated statistically significant improvement in ETDRS visual acuity versus registry control in a Phase 2a CRAO study in Japan (p=0.0398).
In the randomized Phase 2a study in Japan conducted by Senju and its partners, KIO-401 demonstrated a statistically significant improvement from baseline in Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity compared with a prospective, observational registry (p=0.0398).
Filing
3 more on record.
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 2 ophthalmology companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.